Get the Stockscreener App
4.89
1.41%
-0.07
Nextcure Inc stock is traded at $4.89, with a volume of 35,002.
It is down -1.41% in the last 24 hours and up +1,022% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$4.96
Open:
$4.8217
24h Volume:
35,002
Relative Volume:
0.13
Market Cap:
$13.09M
Revenue:
-
Net Income/Loss:
$-58.52M
P/E Ratio:
-2.3397
EPS:
-2.09
Net Cash Flow:
$-45.03M
1W Performance:
-20.75%
1M Performance:
+1,022%
6M Performance:
+507.60%
1Y Performance:
+203.73%
1-Day Range:
$4.80
$5.1533
1-Week Range:
$4.80
$6.265
52-Week Range:
$0.224
$6.42
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
4.89 | 13.27M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
Short interest data insights for NextCure Inc.Quarterly Investment Outlook and Key Summary - Newser
How NextCure Inc. stock performs during market volatilitySafe Entry Screening with Data Backed Analysis - Newser
What makes NextCure Inc. stock price move sharplyShort Term Gain Strategy with AI Logic - Newser
What is the dividend policy of NextCure Inc. stockStock Strategy Insights For Consistent Profits - jammulinksnews.com
Does NextCure Inc. stock perform well during market downturnsFinancial News Planner Backed By Experts - jammulinksnews.com
What are analysts’ price targets for NextCure Inc. in the next 12 monthsDaily Trading Recommendation To Watch Now - jammulinksnews.com
Market reaction to NextCure Inc.’s recent newsFree Community Strategy With High Win Rate - Newser
Why NextCure Inc. stock attracts strong analyst attentionAnnual Market Behavior and Sector Summary - Newser
What the charts say about NextCure Inc. todayAI Trade Signal Forecast with Chart Logic - Newser
Trend Reversal Possible in NextCure Inc. Charts IndicateEarnings Play Trade Plan With Alerts Shared - metal.it
Candlestick Signal Suggests Reversal in NextCure Inc.Entry Alert Based on Volume Spikes Detected - metal.it
Breakout Traders Target NextCure Inc. on Recovery SetupReversal Alert Based on RSI Indicator Confirmed - metal.it
Is NextCure Inc. Stock a Smart Buy in 2025 Investment Analysis Inside Free Real Profit Trade Plan Suggestions - Newser
How many analysts rate NextCure Inc. as a “Buy”Explosive trading opportunities - jammulinksnews.com
Is it the right time to buy NextCure Inc. stockPhenomenal wealth increase - jammulinksnews.com
Is NextCure Inc. a growth stock or a value stockEntry Signal Guidance That Work - jammulinksnews.com
How does NextCure Inc. compare to its industry peersBuild wealth faster with disciplined trading - jammulinksnews.com
What are the latest earnings results for NextCure Inc.Free Bull & Bear Market Updates - jammulinksnews.com
What institutional investors are buying NextCure Inc. stockStay informed with daily expert analysis - jammulinksnews.com
NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment - MSN
NextCure Inc. Company Revenue and Profit Trends: A Deep DiveFree Best Stocks to Buy Today - Newser
Top Risks to Consider Before Buying NextCure Inc. StockFree Stock Selection - Newser
NextCure Inc. Earnings Report Breakdown: What Investors Should KnowWealth Building Stock Portfolio - Newser
Is NextCure Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree High-Profit Stock Picks - Newser
Is NextCure Inc. a good long term investmentGame-changing returns - PrintWeekIndia
NXTC Stock: Exploring Nextcure Inc’s Growth - investchronicle.com
NextCure Soared 19.01%, What’s Brewing in the Lab That’s Sparking a Biotech Breakout? - AInvest
What drives NextCure Inc. stock priceConsistent double returns - PrintWeekIndia
NextCure stock soars after positive data for bone disease treatment By Investing.com - Investing.com Nigeria
NextCure stock soars after positive data for bone disease treatment - Investing.com Australia
Nextcure’s anti-Siglec-15 mAb improves bone architecture in murine model - BioWorld MedTech
What analysts say about NextCure Inc. stockUnstoppable investment returns - PrintWeekIndia
NextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate - Nasdaq
NextCure Soars 23.57% on Promising Bone Disease Data - AInvest
NextCure Inc. Stock Analysis and ForecastPhenomenal returns - Autocar Professional
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta - The Manila Times
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease - 富途牛牛
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):